Increased incidence and reduced mortality after first attack of acute pancreatitis over an 18-year period

Vinge-Holmquist, Olof; Benth, Jūratė Šaltytė; Arno, E.; Langbach, Odd; Røkke, Ola

doi:10.1080/00365521.2023.2235452

Cited by 1 publication

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, there has been a marked increase in the incidence of acute pancreatitis of unspecified aetiology, suggesting the possibility that SARS-CoV-2 may be an etiological factor in the development of this condition ( 2-4 ). This perspective raises the need for further research to investigate potential links between SARS-CoV-2 infection and AIP, thus contributing to a better understanding of this complex condition.…”

Section: Introductionmentioning

confidence: 99%

Treatment approaches in autoimmune pancreatitis (Review)

Pădureanu,

Drăgoescu,

Pădureanu

et al. 2023

Biomed Rep

View full text Add to dashboard Cite

Autoimmune pancreatitis (AIP) is a rare disease. There are two distinct types of AIP: AIP type 1 (AIP-1), a pancreatic manifestation of a multi-organ disease linked to immunoglobulin (Ig)G4, and AIP type 2 (AIP-2), a pancreas-specific disease unrelated to IgG4. The usual course of treatment for AIP is oral corticosteroid medication. Rituximab has also been recommended for recurrent AIP-1 in order to initiate remission and provide ongoing treatment. Immunomodulators such as azathioprine are used to keep certain patients in remission. Evaluation also takes into account a number of pharmacological alternatives, including biologic drugs like anti-tumor necrosis factor therapy, a safe and efficient second-line treatment for AIP-2 relapse or steroid dependence. Corticosteroids and immunosuppressants, which are poorly tolerated due to considerable side effects, are being replaced by other biologic drugs, which may offer a beneficial therapeutic alternative.

show abstract

Section: Introductionmentioning

confidence: 99%